Physician profile
Chen Zhou
NPI 1528556123
$3,022.80
in general payments reported to CMS, 2019-2025
25 companies · $824 in 2025
The $824 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $874 · 2024: $1,154 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $611.90 | 2023-2024 | Jornay Pm |
| Abbvie INC. | $422.19 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $306.42 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $295.11 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $259.04 | 2022-2025 | Auvelity |
| Eisai INC. | $172.53 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $128.27 | 2023-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.94 | 2023-2025 | Caplyta |
| Harmony Biosciences LLC | $87.08 | 2022-2023 | Wakix |
| Collegium Pharmaceutical, INC. | $77.75 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $69.63 | 2024-2025 | Qelbree |
| Braeburn INC. | $64.03 | 2024-2025 | Brixadi |
| Almatica Pharma LLC | $54.92 | 2024-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $54.64 | 2025 | Fanapt |
| Tris Pharma INC | $46.31 | 2023-2024 | Dyanavel Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $41.14 | 2024-2025 | Zurzuvae |
| Bausch Health US, LLC | $40.60 | 2022-2023 | Aplenzin, Wellbutrin |
| Janssen Scientific Affairs, LLC | $31.50 | 2024 | Spravato |
| Indivior INC. | $24.45 | 2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $22.54 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.07 | 2023 | Quviviq |
| Corium, LLC | $21.01 | 2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $19.77 | 2025 | Relexxii |
| Lundbeck LLC | $18.87 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.